Matching the drug to the tumour

Cancer treatment is shifting from anatomy to biology. What matters increasingly is which mutation drives the tumour rather than which organ it started in, and that shift makes the diagnostic test the gate through which the therapy passes.

Historically oncology treated by tissue of origin with cytotoxic chemotherapy. Targeted therapies and immunotherapies changed the logic, and each new targeted drug creates demand for the test that identifies who should receive it.

The structural driver is the drug pipeline. Every approval of a targeted agent expands the population that needs profiling, and profiling volume grows with each approval regardless of which company wins.

The technology layer spans comprehensive genomic profiling of tumour tissue, liquid biopsy detecting circulating tumour DNA, minimal residual disease monitoring after treatment, multi cancer early detection, and the interpretation software that turns variants into a treatment recommendation.

Adoption economics hinge on reimbursement. Comprehensive profiling costs more than single gene testing, and coverage decisions determine whether it is used broadly or reserved for late line patients.

The beneficiaries include diagnostic laboratories running profiling at volume, liquid biopsy developers, sequencing platform suppliers, interpretation software firms, and the pharmaceutical companies whose drugs depend on companion tests.

The value chain runs from sample through sequencing and interpretation to treatment decision and reimbursement. Payer coverage is the gate that decides volume.

The overlooked layer includes sample preparation and pathology services, bioinformatics interpretation vendors, clinical decision support tools, and the biobanking infrastructure behind research.

Competitive dynamics involve laboratories competing on turnaround, breadth of panel, and payer coverage, with pharmaceutical partnerships providing a route to guaranteed volume.

Risks: reimbursement decisions gate everything, laboratory economics are pressured by pricing, clinical validation is expensive and slow, and multi cancer screening still needs outcome evidence.

What to watch: coverage decisions for comprehensive profiling, targeted therapy approvals, liquid biopsy validation studies, and testing volumes at major laboratories.